// App-Quantinova.ai

: Alliance A032002 (ART): Phase II randomized trial of atezolizumab versus atezolizumab and radiation therapy for platinum-ineligible/refractory metastatic urothelial cancer.

Researchers

Presenter

  • Himanshu Nagar

Principal Investigators

  • Karla V. Ballman

  • Scott T. Tagawa

  • Alan Tan

  • Bishoy Morris Faltas

  • Arshin Sheybani

  • Shiva Baghaie

  • Lawrence Howard Schwartz

  • David E. Kozono

  • Jeffrey A Bogart

  • Olivia Conway

  • Gina L. Mazza

  • Ronald C. Chen

  • Andrew Leonard Laccetti

  • Jonathan E. Rosenberg

  • Michael J. Morris

Medical Centers

  • Alliance for Clinical Trials in Oncology, Durham, NC

  • Memorial Sloan Kettering, New York, NY

  • Mayo Clinic, Rochester, MN

  • University of Iowa Hospitals and Clinics, Iowa City, IA

  • Mayo Clinic, Phoenix, AZ

  • University of Kansas Medical Center, Kansas City, MO

  • Weill Cornell Medical College of Cornell University, New York, NY

  • Upstate Medical University, Syracuse, NY

  • Weill Cornell Medicine, New York, NY

  • Columbia University Medical Center, New York, NY

  • Dana-Farber Cancer Institute, Boston, MA

  • Rush University Medical Center, Chicago, IL

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

Disease

  • Advanced Urothelial Carcinoma

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Atezolizumab

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • II

Study Id's

  • NCT04936230

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved